Dr. Reddy's Lab gets approval for Aspirin, extended-release Dipyridamole Capsules

15 Oct 2018 Evaluate

Dr. Reddy's Laboratories has received an approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the US Food and Drug Administration (USFDA). The company is working towards launching the product.

The Aggrenox brand and generic had US sales of around $183 million MAT for the most recent twelve months ending in August 2018 according to IMS Health. Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

5955.65 71.30 (1.21%)
28-May-2024 15:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1464.85
Dr. Reddys Lab 5955.65
Cipla 1477.15
Zydus Lifesciences 1050.35
Lupin 1603.55
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.